• Explore /
  • Poster
  • / Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in <i>KRAS </i>G12C altered NSCLC according to PD-L1 status.

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.

Abstract Poster

Authors

Charu Aggarwal

Charu Aggarwal

University of Pennsylvania, Philadelphia, PA

Charu Aggarwal , Lamisa Parkar , Iker Huerga , Kate Sasser , Halla Nimeiri , Beata Korytowsky , Jyoti D. Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9136)

DOI

10.1200/JCO.2023.41.16_suppl.9136

Abstract #

9136

Poster Bd #

124

Abstract Disclosures

Similar Posters

First Author: Jordan Kardos

First Author: Arielle Elkrief

Poster

2022 ASCO Annual Meeting

Molecular characterization of NF1-mutated NSCLC and clinical outcomes.

Molecular characterization of NF1-mutated NSCLC and clinical outcomes.

First Author: Christopher Gates

First Author: Samuel Rosner